Anzeige
Mehr »
Freitag, 07.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4QR | ISIN: US98420X2027 | Ticker-Symbol: 48Q0
Lang & Schwarz
07.08.26 | 07:00
2,450 Euro
-100,00 % -2,450
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
X4 PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
X4 PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4402,46007:00

Aktuelle News zur X4 PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
X4 PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoX4 Pharmaceuticals GAAP EPS of -$0.13 beats by $0.05, revenue of $8.81M beats by $6.39M1
DoX4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update58- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First...
► Artikel lesen
MoX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2
10.07.Wells Fargo initiates X4 Pharmaceuticals stock coverage with overweight rating4
07.07.X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
01.07.X4 Pharmaceuticals, Inc - 8-K, Current Report10
01.07.X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors130BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly...
► Artikel lesen
02.06.Leerink stuft X4 Pharmaceuticals mit "Outperform" ein und sieht erhebliches Kurspotenzial5
02.06.Leerink initiates X4 Pharmaceuticals stock with outperform rating2
01.06.X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
14.05.Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now7
12.05.X4 Pharmaceuticals, Inc - 8-K, Current Report1
07.05.X4 Pharmaceuticals GAAP EPS of -$0.16 beats by $0.04, revenue of $2.71M beats by $0.88M2
06.05.X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates1
06.05.X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update335- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized...
► Artikel lesen
06.05.X4 Pharmaceuticals, Inc - 10-Q, Quarterly Report-
29.04.X4 Pharmaceuticals gets EU approval for WHIM syndrome drug18
01.04.X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
17.03.Stifel reiterates X4 Pharmaceuticals stock rating on trial progress2
17.03.X4 Pharmaceuticals GAAP EPS of -$0.22 beats by $0.13, revenue of $2.57M beats by $0.84M2
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1